The National Institutes of Health (NIH) is a critical pillar of the U.S. public health system and a beacon of guidance for healthcare best practices across the globe. This has never been more evident than during the COVID-19 crisis. A lesser-known NIH facet is its long and productive history of technology transfer success.
One of the leaders in the DE&I biotech space has been Gilead, the parent company of Kite, which launched a robust, action-oriented DE&I initiative in 2019. Gilead and Kite have made concerted efforts to improve workplace culture for underrepresented groups; they currently have programs focused on advancing black leadership, developing diverse talent, building diversity representation goals, establishing pay equity, and working with its partners on DE&I efforts.
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-CELL Therapy Manufacturing Facility in Maryland
Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.
Several biotech companies worked with Frederick to design the Biotech Bootcamp curriculum and interviewed participants after the month-long program, which they will do again this round. Of the 14 students who completed the first Biotech Bootcamp, ten have landed positions at Frederick County biotech companies, including Lonza, Ellume, and Kite Pharma. Some also accepted positions at Rockville-based Meso Scale Diagnostics.
2022 ISPE Mid-Atlantic Science & Technology Showcase Brings the Local Life Science Community Back Together
After 2 (long) years, the widely-popular ISPE Mid-Atlantic Science & Technology (MAST) Showcase was back in person, with excitement and energy filling the rooms as professionals from across the BioHealth Capital Region and beyond gathered at the Turf Valley Resort in Ellicott City, MD.
As Kite, a Gilead Company continues to grow its footprint, sustainability remains a commitment. Its newest state-of-the-art cell therapy manufacturing facility located along the I-270 corridor in Urbana, Maryland was built in accordance with LEED criteria and BREEAM standards, according to a press release.
The BHCR cluster, in particular, includes a host of emerging and established cell and gene therapy companies, as well one of the deepest and most advanced biomanufacturing infrastructures in the U.S. While the cell and gene therapy industry still faces challenges like high manufacturing costs, high cost per dose to patients and complex supply chain issues, this sector remains very healthy and is continuing to grow rapidly in our region and globally.
In April of 2019, Kite, a Gilead Company, announced their decision to locate to Frederick County, MD and open a new manufacturing facility on a 20-acre site located at the Urbana Corporate Center. A lot of progress has happened since then; Kite finished their brand new 279,000 SF biologics manufacturing facility in April 2021. To learn more, Solash Aviles and Jodie Bollinger from the Frederick County Office of Economic Development met with Chris McDonald, Senior Vice President, Global Head of Manufacturing at Kite and Jim Jackson, Vice President, Manufacturing Operations and Site Head at Kite.
Congressman David Trone (MD-06) and Deputy Secretary of Commerce Don Graves toured Kite Pharma with the Maryland Tech Council on Friday.
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.